Covid-19 Innovation Challenges by Innoget

SARS-CoV-2 NSP16 Targeted Library

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Innovative Products and Technologies · United Kingdom

Summary of the technology

SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).

Covid-19 Innovation Challenges by Innoget

Description of the technology

2′-O-methyltransferase (2′-O-MTase, non-structural protein 16, nsp16) can act as potential drug target for the SARS-CoV-2. It prevents recognition and activation of the host immune response which is essential for successful viral infection. OTAVAchemicals offers SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library (1049 compounds with predicted activity against SARS-CoV-2 NSP16). The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ). The overall procedure included accurate flexible docking of Drug-like Green Collection into methyltransferase catalytic site. Final selection of compounds was made with inspection of enzyme active site’s crucial structural determinants for ligand binding, docking scores and intermolecular hydrogen bonds with key active site’s amino acid residues.

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Related keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Diagnostics, Diagnosis
  • Medical Research
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Infectious Diseases
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Other Medical/Health Related
  • Covid-19
  • coronavirus
  • sars-cov-s

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.